Last $0.23 USD
Change Today 0.00 / 0.00%
Volume 0.0
CNSO On Other Exchanges
Symbol
Exchange
OTC US
OTC US
As of 8:10 PM 09/26/14 All times are local (Market data is delayed by at least 15 minutes).

cns response inc (CNSO) Snapshot

Open
$0.24
Previous Close
$0.23
Day High
$0.24
Day Low
$0.22
52 Week High
01/13/14 - $0.90
52 Week Low
09/24/14 - $0.22
Market Cap
22.9M
Average Volume 10 Days
2.7K
EPS TTM
$-0.04
Shares Outstanding
101.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CNS RESPONSE INC (CNSO)

cns response inc (CNSO) Related Bloomberg News

View More Bloomberg News

cns response inc (CNSO) Related Businessweek News

No Related Businessweek News Found

cns response inc (CNSO) Details

CNS Response, Inc. operates as a clinical decision support company with a patented commercial neurometric platform to predict drug response for the treatment of brain disorders, including depression, anxiety, bipolar disorder, and post-traumatic stress disorder. It provides reference data and analytic tools for clinicians and researchers in psychiatry. The company’s Psychiatric EEG Evaluation Registry (PEER) Online, a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). CNS Response, Inc. is headquartered in Aliso Viejo, California.

7 Employees
Last Reported Date: 12/23/13

cns response inc (CNSO) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $228.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $167.6K
Medical Director
Total Annual Compensation: $89.3K
Compensation as of Fiscal Year 2013.

cns response inc (CNSO) Key Developments

CNS Response, Inc. Conducts Clinical Study of its PEER Technology by Walter Reed National Military Medical Center

CNS Response, Inc. is conducting a clinical study of its PEER technology led by Walter Reed National Military Medical Center. The analysis of the interim study data has been undertaken and statistically significant results, which are consistent with prior clinical studies, have been achieved. The study's Principal Investigator and co-authors have written a scientific paper summarizing these interim findings. This paper has been submitted for pre-publication peer review and responses to the peer-reviewer's comments are being finalized. Subject to these responses, acceptance of the paper for publication is anticipated. The draft scientific paper was submitted to the WRNMMC Institutional Review Board (the "IRB") for their review on May 15, 2014. Subsequently, the IRB has suspended its approval for the enrollment of new subjects into the study until they have had an opportunity to perform and complete an examination of certain issues identified during a routine audit. The IRB has determined that treatment of subjects, currently enrolled in the study under the existing study protocol, may be continued. The study's Principal Investigator is working closely with the IRB to address any and all questions to resolve outstanding issues.

CNS Response, Inc. Proposes Amendment to Certificate of Incorporation

CNS Response, Inc. announced that the annual general meeting to be held on May 13, 2014, the board proposed the amend the company's amended and restated certificate of incorporation, as amended in order to increase the number of shares of common stock, par value $0.001 per share, authorized for issuance under the charter from $150,000,000 to $180,000,000.

CNS Response, Inc., Annual General Meeting, May 13, 2014

CNS Response, Inc., Annual General Meeting, May 13, 2014., at 08:00 Pacific Standard Time. Location: The Pacific Club, 4110 Mac Arthur Blvd.. Agenda: To consider and elect seven directors to serve until the next annual meeting of stockholders and until their successors are elected and qualified; to amend the company's amended and restated certificate of incorporation, as amended in order to increase the number of shares of common stock, par value $0.001 per share, authorized for issuance under the Charter from $150,000,000 to $180,000,000; to ratify the selection by the audit committee of Anton & Chai LLP as independent registered accounting firm for the fiscal year ending September 30, 2014; and to transact such other business as may properly come before the annual meeting and any meeting following postponement or adjournment thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CNSO:US $0.23 USD 0.00

CNSO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Brain Resource Ltd A$0.26 AUD 0.00
Genomic Health Inc $28.54 USD +0.23
International Business Machines Corp $187.17 USD -2.66
View Industry Companies
 

Industry Analysis

CNSO

Industry Average

Valuation CNSO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 143.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 144.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CNS RESPONSE INC, please visit www.CNSResponse.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.